GastroGard® approved as the first imported equine drug in China as Boehringer Ingelheim officially starts equine business in the country

  • GastroGard® is a globally renowned product and the only drug approved by the US FDA for the prevention and treatment of gastric ulcers in horses
  • Boehringer Ingelheim becomes the first multinational animal health company with an equine business in China
  • The company is committed to introducing leading equine drugs into China and supporting the upgrading of the local equine industry

Shanghai, China, May 12, 2021 - Boehringer Ingelheim, a global leader in animal health, announced that GastroGard® (omeprazole oral paste) has been granted the Registration Certificate of Imported Veterinary Drug by the Ministry of Agriculture and Rural Affairs of China, making it the first equine drug approved to be imported into the China market. GastroGard® is the preferred drug for equine gastric ulcers among veterinarians worldwide and is currently the only veterinary drug approved by the FDA for the treatment and prevention of equine gastric ulcers in the United States.

Equine gastric ulcer syndrome is caused by factors such as feeding patterns, diet and stress. It is a high-risk disease in horses with all types and ages. Studies showed that the incidence rate in race horses was up to 80-100 percent, and that in non-race horses was also as high as 11 percent. If not diagnosed in a timely manner, the disease can be ignored and treatment can be delayed, which may lead to chronic gastric ulcers accompanied by lesions in the long term. The common manifestations of chronic gastric ulcers are weight loss, loss of appetite, poor coat conditions, and recurrent abdominal pain, seriously affecting the sports performance of horses.

According to the Survey Report on the Development of China’s Equestrian Industry in 2019, China had more than 3.6 million horses and more and more Chinese people are beginning to experience equestrian sports. As of August 31, 2019, China had 2,160 equestrian clubs. In addition, horses are increasingly used for the purpose of tourism and treatment, as well as being raised as pets. However, China still lacks equine products, which severely hinders the development of the equine industry. “Hence it is urgent for us to develop professional equine veterinarians, focus on the research and development of innovative drugs and accelerate the introduction of high-quality equine drugs,” said Academician Jianzhong Shen from China Agricultural University. “The domestic clinical trial data of GastroGard® prove it to be a high-quality therapy for gastric ulcer, a high-risk disease in horses. Clinically, it will improve the sports performances and well-being of horses, thus bringing benefits to the equine industry in China,” shared Associate Professor Zhi Wang from Inner Mongolia Agricultural University.

With the motto “in China, for China,” Boehringer Ingelheim is committed to providing customers with better and innovative solutions as well as high-quality services to upscale the industry and improve the health of both humans and animals. “The registration of GastroGard® marks that the company has started its equine business in China, and so become the first among all multinational animal health companies with a presence in the equine industry in the country. We look forward to contributing to the improvement of health and well-being of horses in China and transforming the local equine industry, while catering to the wishes of the Chinese people to live a better life,” said David Gocken, Head of Animal Health for the Chinese Markets, Boehringer Ingelheim.

By launching the equine health business in China, Boehringer Ingelheim will accelerate the introduction of high-quality innovative products, bring leading treatment solutions to equine veterinarians and support the development of the equine industry in China.

Please note that this a shortened version of the press release not including references and footnotes. For the full version, please follow this link.

More information about Boehringer Ingelheim can be found on
our website or in our annual report.